| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Renal Dialysis | 65 | 2025 | 948 | 9.940 |
Why?
|
| Kidney Failure, Chronic | 56 | 2025 | 930 | 8.530 |
Why?
|
| Renal Insufficiency, Chronic | 49 | 2026 | 852 | 6.630 |
Why?
|
| Glomerular Filtration Rate | 42 | 2026 | 566 | 5.650 |
Why?
|
| Kidney | 13 | 2024 | 1280 | 2.850 |
Why?
|
| Cardiovascular Diseases | 29 | 2026 | 2111 | 2.310 |
Why?
|
| Kidney Function Tests | 8 | 2023 | 135 | 2.200 |
Why?
|
| Urea | 5 | 2025 | 219 | 1.780 |
Why?
|
| Death, Sudden, Cardiac | 5 | 2021 | 268 | 1.620 |
Why?
|
| Hypertension | 11 | 2022 | 1352 | 1.610 |
Why?
|
| Cystatin C | 10 | 2022 | 70 | 1.610 |
Why?
|
| Quality of Life | 10 | 2024 | 2074 | 1.410 |
Why?
|
| Biomarkers | 31 | 2025 | 3365 | 1.350 |
Why?
|
| Point-of-Care Systems | 3 | 2019 | 213 | 1.300 |
Why?
|
| Lipocalins | 6 | 2017 | 30 | 1.260 |
Why?
|
| Intramolecular Oxidoreductases | 6 | 2017 | 41 | 1.250 |
Why?
|
| Antihypertensive Agents | 8 | 2020 | 414 | 1.230 |
Why?
|
| Middle Aged | 88 | 2026 | 28420 | 1.220 |
Why?
|
| Electrocardiography, Ambulatory | 2 | 2021 | 61 | 1.200 |
Why?
|
| Iohexol | 3 | 2024 | 19 | 1.150 |
Why?
|
| Indican | 6 | 2019 | 8 | 1.140 |
Why?
|
| Arrhythmias, Cardiac | 5 | 2021 | 482 | 1.090 |
Why?
|
| Risk Assessment | 18 | 2026 | 3687 | 1.080 |
Why?
|
| Humans | 143 | 2026 | 130511 | 1.080 |
Why?
|
| Kidney Diseases | 4 | 2018 | 475 | 1.080 |
Why?
|
| Creatinine | 13 | 2024 | 398 | 1.070 |
Why?
|
| Nephrology | 2 | 2019 | 162 | 0.970 |
Why?
|
| Diabetes Mellitus, Type 2 | 9 | 2026 | 1457 | 0.950 |
Why?
|
| Male | 97 | 2026 | 64586 | 0.910 |
Why?
|
| Aged | 61 | 2026 | 20897 | 0.900 |
Why?
|
| Cresols | 4 | 2017 | 10 | 0.890 |
Why?
|
| Practice Guidelines as Topic | 5 | 2026 | 1287 | 0.880 |
Why?
|
| Risk Factors | 44 | 2026 | 11011 | 0.870 |
Why?
|
| Disease Progression | 12 | 2026 | 2192 | 0.870 |
Why?
|
| Female | 99 | 2026 | 70545 | 0.860 |
Why?
|
| Prospective Studies | 29 | 2022 | 6424 | 0.850 |
Why?
|
| Metabolomics | 5 | 2024 | 500 | 0.820 |
Why?
|
| Troponin I | 2 | 2016 | 121 | 0.820 |
Why?
|
| Heart Failure | 8 | 2026 | 2325 | 0.810 |
Why?
|
| Natriuretic Peptide, Brain | 3 | 2021 | 324 | 0.770 |
Why?
|
| Sulfuric Acid Esters | 3 | 2017 | 15 | 0.750 |
Why?
|
| Blood Pressure | 8 | 2017 | 1344 | 0.730 |
Why?
|
| Peptide Fragments | 3 | 2021 | 686 | 0.720 |
Why?
|
| Cohort Studies | 27 | 2025 | 5048 | 0.680 |
Why?
|
| Diabetic Nephropathies | 5 | 2026 | 115 | 0.680 |
Why?
|
| Clinical Competence | 2 | 2019 | 1046 | 0.670 |
Why?
|
| Kidney Transplantation | 4 | 2025 | 553 | 0.660 |
Why?
|
| Pruritus | 5 | 2024 | 51 | 0.610 |
Why?
|
| Pharmaceutical Preparations | 1 | 2020 | 79 | 0.600 |
Why?
|
| Adult | 50 | 2025 | 31115 | 0.600 |
Why?
|
| United States | 32 | 2025 | 12009 | 0.590 |
Why?
|
| Drug Resistance, Multiple | 1 | 2019 | 53 | 0.580 |
Why?
|
| Cross-Sectional Studies | 17 | 2024 | 3815 | 0.570 |
Why?
|
| Hypotension | 2 | 2017 | 187 | 0.560 |
Why?
|
| Death | 1 | 2019 | 78 | 0.550 |
Why?
|
| Peritoneal Dialysis | 3 | 2017 | 133 | 0.550 |
Why?
|
| Ultrasonography, Doppler | 1 | 2019 | 187 | 0.540 |
Why?
|
| Methylamines | 2 | 2023 | 20 | 0.540 |
Why?
|
| Dialysis Solutions | 4 | 2020 | 17 | 0.530 |
Why?
|
| Patient Education as Topic | 1 | 2021 | 461 | 0.530 |
Why?
|
| Serum Albumin | 3 | 2017 | 101 | 0.530 |
Why?
|
| Hemodialysis, Home | 1 | 2017 | 13 | 0.520 |
Why?
|
| Autonomic Nervous System Diseases | 1 | 2017 | 41 | 0.520 |
Why?
|
| Venous Pressure | 1 | 2016 | 11 | 0.490 |
Why?
|
| Vena Cava, Inferior | 1 | 2016 | 93 | 0.460 |
Why?
|
| Arginine | 2 | 2023 | 335 | 0.460 |
Why?
|
| Atherosclerosis | 8 | 2023 | 947 | 0.450 |
Why?
|
| Nutrition Surveys | 2 | 2019 | 332 | 0.450 |
Why?
|
| Hospitalization | 5 | 2018 | 1942 | 0.440 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2021 | 914 | 0.430 |
Why?
|
| Fructosamine | 2 | 2017 | 10 | 0.420 |
Why?
|
| Systole | 2 | 2014 | 195 | 0.410 |
Why?
|
| Iron | 4 | 2021 | 305 | 0.400 |
Why?
|
| Health Equity | 2 | 2025 | 78 | 0.400 |
Why?
|
| Vascular Calcification | 3 | 2022 | 70 | 0.400 |
Why?
|
| Precision Medicine | 1 | 2017 | 386 | 0.390 |
Why?
|
| Cause of Death | 7 | 2019 | 502 | 0.380 |
Why?
|
| Arteriovenous Shunt, Surgical | 3 | 2019 | 86 | 0.380 |
Why?
|
| Healthcare Disparities | 3 | 2025 | 516 | 0.370 |
Why?
|
| beta 2-Microglobulin | 4 | 2017 | 35 | 0.370 |
Why?
|
| Hypokalemia | 2 | 2011 | 41 | 0.360 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2017 | 511 | 0.360 |
Why?
|
| Uremia | 3 | 2024 | 33 | 0.360 |
Why?
|
| Focus Groups | 2 | 2025 | 239 | 0.360 |
Why?
|
| Diabetes Mellitus | 5 | 2023 | 888 | 0.340 |
Why?
|
| Blood Volume | 3 | 2016 | 73 | 0.340 |
Why?
|
| Mineralocorticoid Receptor Antagonists | 3 | 2026 | 45 | 0.340 |
Why?
|
| Patient-Centered Care | 3 | 2025 | 236 | 0.340 |
Why?
|
| Follow-Up Studies | 13 | 2019 | 5185 | 0.330 |
Why?
|
| Polyomavirus Infections | 1 | 2011 | 87 | 0.330 |
Why?
|
| Proteinuria | 3 | 2021 | 108 | 0.320 |
Why?
|
| Proportional Hazards Models | 8 | 2019 | 1409 | 0.320 |
Why?
|
| Pain | 2 | 2022 | 437 | 0.300 |
Why?
|
| Predictive Value of Tests | 9 | 2020 | 2298 | 0.290 |
Why?
|
| Health Services Accessibility | 2 | 2025 | 707 | 0.290 |
Why?
|
| Atrial Fibrillation | 3 | 2021 | 736 | 0.290 |
Why?
|
| Chlorthalidone | 1 | 2008 | 25 | 0.290 |
Why?
|
| Hippurates | 3 | 2017 | 7 | 0.280 |
Why?
|
| Prognosis | 9 | 2021 | 4866 | 0.270 |
Why?
|
| Renal Insufficiency | 2 | 2023 | 256 | 0.270 |
Why?
|
| Incidence | 8 | 2023 | 3336 | 0.260 |
Why?
|
| Graft Rejection | 1 | 2011 | 540 | 0.260 |
Why?
|
| Immunosuppressive Agents | 1 | 2011 | 652 | 0.260 |
Why?
|
| Time Factors | 11 | 2024 | 6169 | 0.250 |
Why?
|
| Mortality | 5 | 2018 | 264 | 0.250 |
Why?
|
| Fatigue | 3 | 2024 | 191 | 0.250 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 4 | 2025 | 214 | 0.250 |
Why?
|
| Feeding Behavior | 1 | 2012 | 712 | 0.250 |
Why?
|
| Potassium | 4 | 2013 | 263 | 0.240 |
Why?
|
| Naphthyridines | 1 | 2026 | 14 | 0.240 |
Why?
|
| Paresthesia | 2 | 2024 | 9 | 0.230 |
Why?
|
| Antiviral Agents | 1 | 2011 | 805 | 0.230 |
Why?
|
| Prevalence | 5 | 2020 | 2693 | 0.230 |
Why?
|
| Goat Diseases | 1 | 2025 | 2 | 0.220 |
Why?
|
| Morbidity | 2 | 2017 | 256 | 0.220 |
Why?
|
| Orf virus | 1 | 2025 | 5 | 0.220 |
Why?
|
| Ecthyma, Contagious | 1 | 2025 | 6 | 0.220 |
Why?
|
| Glutamine | 2 | 2017 | 200 | 0.220 |
Why?
|
| Fellowships and Scholarships | 2 | 2019 | 326 | 0.220 |
Why?
|
| Acute Kidney Injury | 3 | 2019 | 702 | 0.220 |
Why?
|
| Retrospective Studies | 13 | 2024 | 17650 | 0.220 |
Why?
|
| Longitudinal Studies | 6 | 2021 | 1484 | 0.210 |
Why?
|
| Models, Biological | 3 | 2024 | 1371 | 0.210 |
Why?
|
| Proteomics | 2 | 2025 | 616 | 0.210 |
Why?
|
| Hypertension, Malignant | 1 | 2004 | 7 | 0.210 |
Why?
|
| Hand Strength | 1 | 2024 | 58 | 0.210 |
Why?
|
| Hyperoxaluria | 1 | 2023 | 6 | 0.200 |
Why?
|
| Trust | 1 | 2025 | 88 | 0.200 |
Why?
|
| Adrenergic beta-Antagonists | 2 | 2017 | 216 | 0.200 |
Why?
|
| Survival Rate | 9 | 2024 | 2109 | 0.200 |
Why?
|
| Hyperparathyroidism, Secondary | 1 | 2023 | 17 | 0.200 |
Why?
|
| Oxalates | 2 | 2023 | 22 | 0.200 |
Why?
|
| Treatment Outcome | 15 | 2026 | 12851 | 0.190 |
Why?
|
| Comorbidity | 6 | 2017 | 1589 | 0.190 |
Why?
|
| Serotonin Syndrome | 1 | 2002 | 1 | 0.190 |
Why?
|
| Meperidine | 1 | 2002 | 5 | 0.190 |
Why?
|
| Cyclohexanols | 1 | 2002 | 9 | 0.190 |
Why?
|
| Amitriptyline | 1 | 2002 | 27 | 0.190 |
Why?
|
| Surveys and Questionnaires | 5 | 2021 | 4057 | 0.190 |
Why?
|
| Hospitalists | 1 | 2003 | 54 | 0.190 |
Why?
|
| Substance Abuse, Intravenous | 1 | 2002 | 42 | 0.180 |
Why?
|
| Practice Patterns, Physicians' | 3 | 2020 | 787 | 0.180 |
Why?
|
| Aged, 80 and over | 11 | 2019 | 6772 | 0.180 |
Why?
|
| Resilience, Psychological | 1 | 2023 | 84 | 0.180 |
Why?
|
| Analgesics | 1 | 2002 | 120 | 0.170 |
Why?
|
| Coronary Artery Disease | 2 | 2022 | 887 | 0.170 |
Why?
|
| Anemia | 2 | 2017 | 354 | 0.170 |
Why?
|
| Blood Glucose Self-Monitoring | 1 | 2022 | 129 | 0.170 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 2002 | 150 | 0.170 |
Why?
|
| Symptom Assessment | 2 | 2021 | 108 | 0.170 |
Why?
|
| Renin | 1 | 2021 | 75 | 0.170 |
Why?
|
| Contrast Media | 1 | 2024 | 476 | 0.160 |
Why?
|
| Machine Learning | 1 | 2025 | 380 | 0.160 |
Why?
|
| Abdominal Fat | 1 | 2020 | 22 | 0.160 |
Why?
|
| Hypertension, Pregnancy-Induced | 1 | 2021 | 80 | 0.160 |
Why?
|
| Incretins | 1 | 2020 | 26 | 0.160 |
Why?
|
| Body Surface Area | 1 | 2020 | 36 | 0.160 |
Why?
|
| Drug Approval | 1 | 2020 | 48 | 0.160 |
Why?
|
| Patients | 1 | 2021 | 122 | 0.160 |
Why?
|
| Bayes Theorem | 1 | 2021 | 307 | 0.160 |
Why?
|
| Blood Glucose | 2 | 2022 | 1112 | 0.150 |
Why?
|
| Peritoneal Dialysis, Continuous Ambulatory | 1 | 2020 | 22 | 0.150 |
Why?
|
| Hypertrophy, Left Ventricular | 2 | 2023 | 108 | 0.150 |
Why?
|
| United States Food and Drug Administration | 1 | 2020 | 158 | 0.150 |
Why?
|
| Minerals | 1 | 2019 | 58 | 0.150 |
Why?
|
| Ketone Bodies | 1 | 2019 | 41 | 0.150 |
Why?
|
| Proof of Concept Study | 1 | 2019 | 41 | 0.150 |
Why?
|
| Waiting Lists | 1 | 2021 | 249 | 0.150 |
Why?
|
| Blood Pressure Determination | 2 | 2014 | 118 | 0.140 |
Why?
|
| Immunologic Factors | 1 | 2020 | 190 | 0.140 |
Why?
|
| Frailty | 1 | 2021 | 140 | 0.140 |
Why?
|
| Caregivers | 1 | 2025 | 596 | 0.140 |
Why?
|
| Academic Medical Centers | 1 | 2020 | 321 | 0.140 |
Why?
|
| Vascular Grafting | 1 | 2018 | 51 | 0.140 |
Why?
|
| Body Size | 1 | 2018 | 62 | 0.140 |
Why?
|
| Hematuria | 1 | 2018 | 48 | 0.140 |
Why?
|
| Reproducibility of Results | 4 | 2022 | 2897 | 0.140 |
Why?
|
| ROC Curve | 2 | 2020 | 613 | 0.140 |
Why?
|
| Pulmonary Edema | 1 | 2018 | 54 | 0.130 |
Why?
|
| Cluster Analysis | 1 | 2019 | 412 | 0.130 |
Why?
|
| Algorithms | 3 | 2021 | 1669 | 0.130 |
Why?
|
| Diabetes Complications | 3 | 2019 | 197 | 0.130 |
Why?
|
| Family | 1 | 2021 | 587 | 0.130 |
Why?
|
| Polycystic Kidney Diseases | 1 | 2017 | 31 | 0.130 |
Why?
|
| Glucose | 1 | 2022 | 851 | 0.130 |
Why?
|
| Hepatitis B, Chronic | 1 | 2018 | 84 | 0.130 |
Why?
|
| Water-Electrolyte Imbalance | 1 | 2018 | 77 | 0.130 |
Why?
|
| Angiotensin II Type 2 Receptor Blockers | 1 | 2017 | 5 | 0.130 |
Why?
|
| Glycation End Products, Advanced | 2 | 2017 | 25 | 0.130 |
Why?
|
| Glomerulonephritis | 1 | 2017 | 74 | 0.130 |
Why?
|
| Trace Elements | 1 | 2017 | 20 | 0.120 |
Why?
|
| Pilot Projects | 1 | 2021 | 1440 | 0.120 |
Why?
|
| Oliguria | 1 | 2016 | 20 | 0.120 |
Why?
|
| Cardio-Renal Syndrome | 1 | 2016 | 23 | 0.120 |
Why?
|
| Netherlands | 1 | 2016 | 52 | 0.120 |
Why?
|
| Baltimore | 1 | 2016 | 45 | 0.120 |
Why?
|
| Prostheses and Implants | 1 | 2017 | 145 | 0.120 |
Why?
|
| Weight Gain | 2 | 2015 | 384 | 0.120 |
Why?
|
| Defibrillators, Implantable | 1 | 2018 | 215 | 0.120 |
Why?
|
| Body Composition | 1 | 2018 | 544 | 0.110 |
Why?
|
| Hyperglycemia | 1 | 2017 | 233 | 0.110 |
Why?
|
| Pleural Effusion | 1 | 2016 | 103 | 0.110 |
Why?
|
| Linear Models | 2 | 2020 | 687 | 0.110 |
Why?
|
| Insulin Resistance | 1 | 2020 | 686 | 0.110 |
Why?
|
| Renal Replacement Therapy | 1 | 2017 | 168 | 0.110 |
Why?
|
| Phosphorus | 1 | 2015 | 60 | 0.110 |
Why?
|
| Area Under Curve | 1 | 2016 | 304 | 0.110 |
Why?
|
| Dyspnea | 1 | 2016 | 159 | 0.110 |
Why?
|
| Cardiotonic Agents | 1 | 2016 | 138 | 0.110 |
Why?
|
| Iron Compounds | 1 | 2014 | 2 | 0.110 |
Why?
|
| Metabolome | 1 | 2017 | 325 | 0.110 |
Why?
|
| Severity of Illness Index | 3 | 2018 | 3038 | 0.110 |
Why?
|
| Vascular Stiffness | 1 | 2015 | 76 | 0.110 |
Why?
|
| Patient Outcome Assessment | 1 | 2015 | 89 | 0.110 |
Why?
|
| Chi-Square Distribution | 2 | 2014 | 562 | 0.110 |
Why?
|
| Young Adult | 9 | 2021 | 10033 | 0.110 |
Why?
|
| Patient Readmission | 1 | 2018 | 441 | 0.100 |
Why?
|
| Sex Factors | 4 | 2021 | 1349 | 0.100 |
Why?
|
| Body Weight | 2 | 2015 | 985 | 0.100 |
Why?
|
| Logistic Models | 1 | 2019 | 1796 | 0.100 |
Why?
|
| Osteoprotegerin | 1 | 2014 | 9 | 0.100 |
Why?
|
| alpha-2-HS-Glycoprotein | 1 | 2014 | 8 | 0.100 |
Why?
|
| Fibroblast Growth Factors | 1 | 2015 | 172 | 0.100 |
Why?
|
| Early Medical Intervention | 1 | 2014 | 32 | 0.100 |
Why?
|
| Albuminuria | 2 | 2026 | 107 | 0.100 |
Why?
|
| Cognitive Dysfunction | 1 | 2018 | 337 | 0.100 |
Why?
|
| Prescriptions | 1 | 2013 | 46 | 0.100 |
Why?
|
| Curriculum | 1 | 2019 | 792 | 0.100 |
Why?
|
| Incidental Findings | 1 | 2014 | 122 | 0.100 |
Why?
|
| Ultrasonography | 1 | 2018 | 942 | 0.100 |
Why?
|
| Inflammation Mediators | 1 | 2014 | 226 | 0.100 |
Why?
|
| Choice Behavior | 1 | 2014 | 140 | 0.100 |
Why?
|
| Gastrointestinal Diseases | 1 | 2017 | 339 | 0.100 |
Why?
|
| Catheterization, Central Venous | 1 | 2014 | 143 | 0.100 |
Why?
|
| Inflammation | 1 | 2020 | 1481 | 0.090 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 1 | 2018 | 400 | 0.090 |
Why?
|
| Sepsis | 1 | 2017 | 493 | 0.090 |
Why?
|
| Causality | 3 | 2021 | 89 | 0.090 |
Why?
|
| Biomedical Research | 1 | 2018 | 561 | 0.090 |
Why?
|
| Exercise | 1 | 2018 | 891 | 0.090 |
Why?
|
| Registries | 3 | 2014 | 1614 | 0.090 |
Why?
|
| Ventricular Function, Left | 1 | 2015 | 548 | 0.090 |
Why?
|
| Angiotensin Receptor Antagonists | 2 | 2023 | 133 | 0.080 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2025 | 1262 | 0.080 |
Why?
|
| Potassium, Dietary | 1 | 2010 | 13 | 0.080 |
Why?
|
| Residence Characteristics | 1 | 2013 | 294 | 0.080 |
Why?
|
| Heart Ventricles | 1 | 2015 | 749 | 0.080 |
Why?
|
| Administration, Intravenous | 3 | 2017 | 172 | 0.080 |
Why?
|
| Urine | 1 | 2010 | 89 | 0.080 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2011 | 1604 | 0.080 |
Why?
|
| Up-Regulation | 1 | 2012 | 826 | 0.080 |
Why?
|
| Parathyroid Hormone | 2 | 2023 | 83 | 0.080 |
Why?
|
| Erythropoietin | 1 | 2010 | 102 | 0.080 |
Why?
|
| Reserpine | 1 | 2008 | 8 | 0.070 |
Why?
|
| Clinical Decision-Making | 2 | 2025 | 313 | 0.070 |
Why?
|
| Atenolol | 1 | 2008 | 43 | 0.070 |
Why?
|
| Sensitivity and Specificity | 3 | 2020 | 2080 | 0.070 |
Why?
|
| Vitamin D | 2 | 2023 | 193 | 0.070 |
Why?
|
| Health Status Disparities | 1 | 2011 | 280 | 0.070 |
Why?
|
| Quality Improvement | 1 | 2012 | 715 | 0.060 |
Why?
|
| Mississippi | 1 | 2025 | 35 | 0.060 |
Why?
|
| North Carolina | 1 | 2025 | 42 | 0.060 |
Why?
|
| Pennsylvania | 1 | 2025 | 60 | 0.060 |
Why?
|
| Electronic Health Records | 2 | 2025 | 843 | 0.060 |
Why?
|
| Veterans | 1 | 2017 | 1756 | 0.060 |
Why?
|
| Pragmatic Clinical Trials as Topic | 1 | 2025 | 35 | 0.060 |
Why?
|
| Drug Therapy, Combination | 1 | 2008 | 1165 | 0.060 |
Why?
|
| Goats | 1 | 2025 | 30 | 0.060 |
Why?
|
| Comparative Effectiveness Research | 1 | 2025 | 72 | 0.050 |
Why?
|
| Coronary Disease | 2 | 2012 | 623 | 0.050 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2021 | 1069 | 0.050 |
Why?
|
| Metabolic Clearance Rate | 1 | 2024 | 126 | 0.050 |
Why?
|
| Tetrahydroisoquinolines | 1 | 2004 | 6 | 0.050 |
Why?
|
| India | 1 | 2025 | 232 | 0.050 |
Why?
|
| Walking Speed | 1 | 2024 | 19 | 0.050 |
Why?
|
| Angiotensins | 1 | 2023 | 9 | 0.050 |
Why?
|
| Sterols | 1 | 2023 | 16 | 0.050 |
Why?
|
| Nausea | 1 | 2024 | 83 | 0.050 |
Why?
|
| Life Expectancy | 1 | 2024 | 63 | 0.050 |
Why?
|
| Naphthalenes | 1 | 2023 | 37 | 0.050 |
Why?
|
| Oligonucleotides | 1 | 2023 | 94 | 0.050 |
Why?
|
| Europe | 1 | 2024 | 364 | 0.050 |
Why?
|
| DNA, Viral | 1 | 2025 | 447 | 0.050 |
Why?
|
| Pituitary-Adrenal System | 1 | 2023 | 33 | 0.050 |
Why?
|
| Hypothalamo-Hypophyseal System | 1 | 2023 | 57 | 0.050 |
Why?
|
| Aging | 2 | 2023 | 1237 | 0.050 |
Why?
|
| Gait | 1 | 2024 | 141 | 0.050 |
Why?
|
| Vitamins | 1 | 2023 | 110 | 0.050 |
Why?
|
| Employment | 1 | 2023 | 74 | 0.050 |
Why?
|
| Venlafaxine Hydrochloride | 1 | 2002 | 20 | 0.050 |
Why?
|
| Emergencies | 1 | 2004 | 171 | 0.050 |
Why?
|
| Japan | 1 | 2023 | 160 | 0.050 |
Why?
|
| Phylogeny | 1 | 2025 | 688 | 0.050 |
Why?
|
| Fluconazole | 1 | 2002 | 48 | 0.050 |
Why?
|
| Deoxycholic Acid | 1 | 2022 | 14 | 0.050 |
Why?
|
| Hospital Costs | 1 | 2003 | 187 | 0.050 |
Why?
|
| Angioplasty, Balloon, Coronary | 1 | 2003 | 161 | 0.050 |
Why?
|
| Walking | 1 | 2024 | 230 | 0.040 |
Why?
|
| Methadone | 1 | 2002 | 135 | 0.040 |
Why?
|
| Drug Interactions | 1 | 2002 | 236 | 0.040 |
Why?
|
| Primary Prevention | 1 | 2003 | 183 | 0.040 |
Why?
|
| Myalgia | 1 | 2021 | 8 | 0.040 |
Why?
|
| Polymerase Chain Reaction | 1 | 2025 | 1445 | 0.040 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2002 | 125 | 0.040 |
Why?
|
| Vasoconstrictor Agents | 1 | 2022 | 136 | 0.040 |
Why?
|
| Ichthyosis | 1 | 2021 | 32 | 0.040 |
Why?
|
| Brain Ischemia | 1 | 2004 | 266 | 0.040 |
Why?
|
| Age Factors | 2 | 2018 | 2818 | 0.040 |
Why?
|
| Preoperative Period | 1 | 2021 | 90 | 0.040 |
Why?
|
| Unsupervised Machine Learning | 1 | 2021 | 12 | 0.040 |
Why?
|
| Heart Function Tests | 1 | 2021 | 51 | 0.040 |
Why?
|
| Patient Care Team | 1 | 2025 | 559 | 0.040 |
Why?
|
| Stem Cell Transplantation | 1 | 2002 | 225 | 0.040 |
Why?
|
| Stroke Volume | 1 | 2023 | 540 | 0.040 |
Why?
|
| Graft Survival | 2 | 2018 | 459 | 0.040 |
Why?
|
| Transplantation Conditioning | 1 | 2002 | 327 | 0.040 |
Why?
|
| Glucagon-Like Peptide-1 Receptor | 1 | 2020 | 44 | 0.040 |
Why?
|
| Coronary Angiography | 1 | 2003 | 449 | 0.040 |
Why?
|
| Renal Elimination | 1 | 2020 | 11 | 0.040 |
Why?
|
| Quality of Health Care | 1 | 2003 | 413 | 0.040 |
Why?
|
| Postoperative Period | 1 | 2021 | 331 | 0.040 |
Why?
|
| C-Reactive Protein | 1 | 2023 | 448 | 0.040 |
Why?
|
| Body Mass Index | 2 | 2020 | 1704 | 0.040 |
Why?
|
| Antifungal Agents | 1 | 2002 | 290 | 0.040 |
Why?
|
| Blood Urea Nitrogen | 1 | 2020 | 68 | 0.040 |
Why?
|
| Sodium | 1 | 2021 | 280 | 0.040 |
Why?
|
| Kidney Tubules, Proximal | 1 | 2020 | 74 | 0.040 |
Why?
|
| Prealbumin | 1 | 2019 | 27 | 0.040 |
Why?
|
| Drug Utilization | 1 | 2020 | 164 | 0.040 |
Why?
|
| Databases, Factual | 2 | 2014 | 1234 | 0.040 |
Why?
|
| China | 1 | 2020 | 277 | 0.040 |
Why?
|
| Attitude of Health Personnel | 1 | 2025 | 704 | 0.040 |
Why?
|
| Republic of Korea | 1 | 2018 | 45 | 0.040 |
Why?
|
| Decision Making | 1 | 2004 | 714 | 0.030 |
Why?
|
| Bone Density | 1 | 2021 | 366 | 0.030 |
Why?
|
| Vascular Patency | 1 | 2018 | 180 | 0.030 |
Why?
|
| Chromatography, Liquid | 1 | 2019 | 233 | 0.030 |
Why?
|
| Independent Living | 1 | 2018 | 64 | 0.030 |
Why?
|
| Coronary Vessels | 1 | 2022 | 521 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2002 | 1243 | 0.030 |
Why?
|
| Palmitic Acids | 1 | 2017 | 5 | 0.030 |
Why?
|
| Kynurenic Acid | 1 | 2017 | 9 | 0.030 |
Why?
|
| Guanosine | 1 | 2017 | 12 | 0.030 |
Why?
|
| Homovanillic Acid | 1 | 2017 | 30 | 0.030 |
Why?
|
| Length of Stay | 1 | 2003 | 1412 | 0.030 |
Why?
|
| Deoxyglucose | 1 | 2017 | 41 | 0.030 |
Why?
|
| Geriatric Assessment | 1 | 2018 | 183 | 0.030 |
Why?
|
| Community Health Services | 1 | 2017 | 86 | 0.030 |
Why?
|
| Quality Control | 1 | 2017 | 116 | 0.030 |
Why?
|
| Observational Studies as Topic | 1 | 2017 | 103 | 0.030 |
Why?
|
| Hemodialysis Solutions | 1 | 2016 | 7 | 0.030 |
Why?
|
| Fasting | 1 | 2017 | 303 | 0.030 |
Why?
|
| Health Status | 1 | 2018 | 378 | 0.030 |
Why?
|
| Fluid Therapy | 1 | 2017 | 141 | 0.030 |
Why?
|
| Multicenter Studies as Topic | 1 | 2017 | 293 | 0.030 |
Why?
|
| Citrulline | 1 | 2017 | 123 | 0.030 |
Why?
|
| Lipids | 1 | 2019 | 566 | 0.030 |
Why?
|
| Valsalva Maneuver | 1 | 2015 | 8 | 0.030 |
Why?
|
| Photoplethysmography | 1 | 2015 | 11 | 0.030 |
Why?
|
| Iothalamic Acid | 1 | 2015 | 4 | 0.030 |
Why?
|
| Stroke | 1 | 2004 | 1059 | 0.030 |
Why?
|
| Patient Admission | 1 | 2017 | 185 | 0.030 |
Why?
|
| Cross-Over Studies | 1 | 2016 | 239 | 0.030 |
Why?
|
| Hemoglobins | 1 | 2017 | 286 | 0.030 |
Why?
|
| Pulse Wave Analysis | 1 | 2015 | 48 | 0.030 |
Why?
|
| Alkaline Phosphatase | 1 | 2015 | 93 | 0.030 |
Why?
|
| Fingers | 1 | 2015 | 62 | 0.030 |
Why?
|
| Hemostasis | 1 | 2015 | 76 | 0.030 |
Why?
|
| Kinetics | 1 | 2017 | 1087 | 0.030 |
Why?
|
| Survival Analysis | 2 | 2012 | 1480 | 0.030 |
Why?
|
| Obesity | 2 | 2004 | 2416 | 0.030 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2003 | 889 | 0.030 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2017 | 222 | 0.030 |
Why?
|
| Quality Indicators, Health Care | 1 | 2017 | 238 | 0.030 |
Why?
|
| Organ Size | 1 | 2015 | 407 | 0.030 |
Why?
|
| Maryland | 1 | 2014 | 39 | 0.030 |
Why?
|
| Ferritins | 1 | 2014 | 104 | 0.030 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2021 | 744 | 0.030 |
Why?
|
| Bone Morphogenetic Protein 7 | 1 | 2014 | 26 | 0.030 |
Why?
|
| Solitary Pulmonary Nodule | 1 | 2014 | 29 | 0.030 |
Why?
|
| Patient Care | 1 | 2014 | 98 | 0.030 |
Why?
|
| Institutionalization | 1 | 2013 | 13 | 0.030 |
Why?
|
| Osteopontin | 1 | 2014 | 55 | 0.030 |
Why?
|
| Statistics as Topic | 1 | 2014 | 241 | 0.020 |
Why?
|
| Vital Capacity | 1 | 2013 | 81 | 0.020 |
Why?
|
| Cognition | 1 | 2018 | 822 | 0.020 |
Why?
|
| Disease Management | 1 | 2017 | 556 | 0.020 |
Why?
|
| Nursing Homes | 1 | 2013 | 88 | 0.020 |
Why?
|
| Adolescent | 3 | 2018 | 20876 | 0.020 |
Why?
|
| Injections, Intravenous | 1 | 2012 | 238 | 0.020 |
Why?
|
| Hyperkalemia | 1 | 2013 | 68 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2013 | 760 | 0.020 |
Why?
|
| Calcium | 1 | 2015 | 1008 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2014 | 1376 | 0.020 |
Why?
|
| Echocardiography | 1 | 2015 | 1124 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2012 | 1211 | 0.020 |
Why?
|
| Pregnancy | 1 | 2021 | 7475 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2014 | 2061 | 0.010 |
Why?
|
| Insulin | 1 | 2010 | 1145 | 0.010 |
Why?
|
| Animals | 1 | 2025 | 33725 | 0.010 |
Why?
|
| Diastole | 1 | 2004 | 181 | 0.010 |
Why?
|
| Radial Artery | 1 | 2003 | 32 | 0.010 |
Why?
|
| Transplantation, Homologous | 1 | 2002 | 667 | 0.010 |
Why?
|
| Recurrence | 1 | 2002 | 1482 | 0.010 |
Why?
|
| Genetic Variation | 1 | 2004 | 1554 | 0.010 |
Why?
|
| Graft vs Host Disease | 1 | 2002 | 691 | 0.010 |
Why?
|